Drug Profile
Research programme: antituberculosis therapeutics - Takeda/TB Alliance
Latest Information Update: 28 Jul 2020
Price :
$50
*
At a glance
- Originator Takeda
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Tuberculosis